Market Place
Sourcing Support
BioMarin to Present Positive VOXZOGO Data for Achondroplasia in Children
18 Sep 2024 //
PR NEWSWIRE
BioMarin To Present VOXZOGO® Data At Children`s Bone Health Conference
17 Jun 2024 //
PR NEWSWIRE
New Data to be Presented for BioMarin`s VOXZOGO
12 Mar 2024 //
PR NEWSWIRE
BioMarin`s dwarfism therapy gets FDA nod for expanded use
21 Oct 2023 //
PR NEWSWIRE
BioMarin to Present Data Showing Long-Term Benefit of VOXZOGO
21 Sep 2023 //
PRESS RELEASE
BioMarin Receives Positive CHMP Opinion in Europe to Expand Use of VOXZOGO
15 Sep 2023 //
PRESS RELEASE
BioMarin touts Voxzogo sales bump in Q2 results,notes `temporarily tight supply`
01 Aug 2023 //
ENDPTS
BioMarin to Share Data at 2023 ACMG Demonstrating Long-Term Benefit of VOXZOGO
14 Mar 2023 //
PRESS RELEASE
BioMarin, as expected, sees delay to FDA review of hemophilia gene therapy
08 Mar 2023 //
BIOPHARMADIVE
FDA Accepts BioMarin`s Supplemental NDA to Expand Use of VOXZOGO
07 Mar 2023 //
PR NEWSWIRE
EMA Validates Application for Extension of Indication for VOXZOGO
03 Jan 2023 //
PRESS RELEASE
BioMarin Announces MHLW in Japan Granted Approval for VOXZOGO for Injection
21 Jun 2022 //
PRNEWSWIRE
BioMarin reports Phase II data of Voxzogo for achondroplasia
14 Jun 2022 //
CLINICALTRIALSARENA
BioMarin eyes profit, though safety concerns cloud new launch
25 Feb 2022 //
FIERCEPHARMA
BioMarin`s dwarfism drug passes FDA but ethics questions loom
20 Nov 2021 //
PRNEWSWIRE
Biomarin Receives FDA Accelerated Approval for Voxzogo (vosoritide)
19 Nov 2021 //
TRIALSITENEWS
BioMarin`s Voxzogo scores EU`s OK for dwarfism-causing condition
28 Aug 2021 //
FIERCEPHARMA
BioMarin`s Voxzogo (vosoritide) Receives Approval in Europe
26 Aug 2021 //
EMA
BioMarin Completes Full Enrollment in Phase 2 Study of Vosoritide
03 Mar 2021 //
PRNEWSWIRE
FDA Accepts BioMarin`s NDA for Vosoritide to Treat Children
04 Nov 2020 //
PRESS RELEASE
FDA Accepts BioMarin`s NDA for Vosoritide to Treat Children with Achondroplasia
03 Nov 2020 //
PRNEWSWIRE
Food & Drug Administration Accepts BioMarin`s NDA for Vosoritide
02 Nov 2020 //
PRNEWSWIRE
BioMarin submits NDA for controversial achondroplasia drug
22 Aug 2020 //
ENDPTS
European Medicines Agency Validates BioMarin`s Marketing Authorization
13 Aug 2020 //
PRNEWSWIRE
EMA Validates BioMarin`s Marketing Authorization Application for Vosoritide
12 Aug 2020 //
PRNEWSWIRE
BioMarin Submits Marketing Authorization Application to EMA for Vosoritide
24 Jul 2020 //
PRESS RELEASE
BioMarin Submits MKT Authorization Application to EMA for Vosoritide
23 Jul 2020 //
INVESTOR
BioMarin`s dwarfism drug clears phase 3, poised for 2021 launch
17 Dec 2019 //
FIERCE BIOTECH
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.